Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. / Pratt, Craig M; Roy, Denis; Torp-Pedersen, Christian; Wyse, D George; Toft, Egon; Juul-Moller, Steen; Retyk, Enrique; Drenning, David Humphrey; Atrial Arrhythmia Conversion Trial (ACT-III) Investigators.
I: American Journal of Cardiology, Bind 106, Nr. 9, 01.11.2010, s. 1277-83.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation
AU - Pratt, Craig M
AU - Roy, Denis
AU - Torp-Pedersen, Christian
AU - Wyse, D George
AU - Toft, Egon
AU - Juul-Moller, Steen
AU - Retyk, Enrique
AU - Drenning, David Humphrey
AU - Atrial Arrhythmia Conversion Trial (ACT-III) Investigators
N1 - Copyright © 2010 Elsevier Inc. All rights reserved.
PY - 2010/11/1
Y1 - 2010/11/1
N2 - The objective of the present study was to assess the safety and effectiveness of vernakalant hydrochloride injection (RSD1235), a novel antiarrhythmic drug, for the conversion of atrial fibrillation (AF) or atrial flutter to sinus rhythm (SR). Patients with either AF or atrial flutter were randomized in a 1:1 ratio to receive vernakalant (n = 138) or placebo (n = 138) and were stratified by an arrhythmia duration of >3 hours to =7 days (short duration) and 8 to =45 days (long duration). The first infusion of placebo or vernakalant (3 mg/kg) was given for 10 minutes followed by a second infusion of placebo or vernakalant (2 mg/kg) 15 minutes later if the arrhythmia had not terminated. A total of 265 patients were randomized and received treatment. The primary end point was conversion of AF to SR for =1 minute within 90 minutes of the start of the drug infusion in the short-duration AF group. Of the 86 patients receiving vernakalant in the short-duration AF group, 44 (51.2%) demonstrated conversion to SR compared to 3 (3.6%) of the 84 in the placebo group (p
AB - The objective of the present study was to assess the safety and effectiveness of vernakalant hydrochloride injection (RSD1235), a novel antiarrhythmic drug, for the conversion of atrial fibrillation (AF) or atrial flutter to sinus rhythm (SR). Patients with either AF or atrial flutter were randomized in a 1:1 ratio to receive vernakalant (n = 138) or placebo (n = 138) and were stratified by an arrhythmia duration of >3 hours to =7 days (short duration) and 8 to =45 days (long duration). The first infusion of placebo or vernakalant (3 mg/kg) was given for 10 minutes followed by a second infusion of placebo or vernakalant (2 mg/kg) 15 minutes later if the arrhythmia had not terminated. A total of 265 patients were randomized and received treatment. The primary end point was conversion of AF to SR for =1 minute within 90 minutes of the start of the drug infusion in the short-duration AF group. Of the 86 patients receiving vernakalant in the short-duration AF group, 44 (51.2%) demonstrated conversion to SR compared to 3 (3.6%) of the 84 in the placebo group (p
U2 - http://dx.doi.org/10.1016/j.amjcard.2010.06.054
DO - http://dx.doi.org/10.1016/j.amjcard.2010.06.054
M3 - Journal article
VL - 106
SP - 1277
EP - 1283
JO - Am. J. Cardiol.
JF - Am. J. Cardiol.
SN - 0002-9149
IS - 9
ER -
ID: 34116206